KDIGO Controversies Conference
Chronic Kidney Disease: Definition,
Classification, and Prognosis
4-6 October, 2009
London, England
CONFERENCE LEADERS
PLANNING COMMITTEE:
Andrew Levey, MD - Conf. Chair
Tufts Medical Center
Boston, USA
alevey@tufts-nemc.org
Paul de Jong, MD – Conf. Co-Chair
University Hospital Groningen
Groningen, The Netherlands
p.e.de.jong@int.azg.nl
Meguid El Nahas, MD - Conf. Co-Chair
University of Sheffield
Sheffield, UK
m.el-nahas@sheffield.ac.uk
Josef Coresh, MD – Conf. Co-Chair
Johns Hopkins University
Baltimore, USA
coresh@jhu.edu
Bertram Kasiske, MD – KDIGO Co-Chair
Hennepin County Medical Center
Minneapolis, USA
kasis001@um.edu
Kai-Uwe Eckardt, MD – KDIGO Co-Chair
University Hospital Erlangen
Erlangen, Germany
Kai-Uwe.Eckardt@uk-erlangen.de
____________________________________
____________________________________
ANALYTICAL TEAM:
Brad Astor, PhD
Johns Hopkins University
Baltimore, USA
bastor@jhsph.edu
Kunihiro Matsushita, MD, PhD
Johns Hopkins University
Baltimore, USA
kmatsush@jhsph.edu
Ron Gansevoort, MD, PhD
University Hospital Groningen
Groningen, The Netherlands
p.e.de.jong@int.azg.nl
Marije van der Vilde
University Hospital Groningen
Groningen, The Netherlands
m.van.der.velde@int.umcg.nl
Page 1 of 8
CONFERENCE ATTENDEES:
Dennis Andress, MD
Invited Observer
Abbott Labs
Abbott Park, IL USA
dennis.andress@abbott.com
Johannes Ärnlöv, MD, PhD
Uppsala University
Uppsala, Sweden
Uppsala Longitudinal Study of Adult Men
(ULSAM) Study
johan.arnlov@pubcare.uu.se
Brad Astor, PhD
Johns Hopkins University
Baltimore, USA
Third National Health and Nutrition
Examinations Survey (NHANES III)
bastor@jhsph.edu
Robert Atkins, MD
Monash Medical Centre
Clayton VIC, Australia
Australian Diabetes, Obesity and Lifestyle
(AusDiab I & II) Study
Bob.Atkins@med.monash.edu.au
Brendan Barrett, MD
Patient Research Center, St. John's
St. John's, NL, Canada
Canadian Prevention of Renal and Vascular
Endpoints Trial (Can-Prevent)
bbarrett@mun.ca
Shaila Basavappa, MSc, Dphil
Invited Observer
Takeda Pharmaceuticals
Deerfield, IL, USA
sbasavappa@takedaglobal.com
Jeffrey Berns, MD, FACP, FACN
University of Pennsylvania
Philadelphia, USA
jeffrey.berns@uphs.upenn.edu
Henk Bilo, MD, PhD, FRCP
Isala Clinics
Zwolle, The Netherlands
Zwolle Outpatient Diabetes project
Involving Available Care (ZODIAC)
h.j.g.bilo@isala.nl
Eric Cantor, MD
Invited Observer
GE Healthcare, Medical Diagnostics
New York, USA
Eric.Cantor@ge.com
Massimo Cirillo, MD
Second University of Naples
Naples, Italy
Gubbio Population Study
massimo.cirillo@unina2.it
Alan Collins, MD
University of Minnesota
Minneapolis, USA
Kidney Early Evaluation Program (KEEP)
acollins@nephrology.org
Brian Copley, MD
Invited Observer
Bristol-Myers Squibb
Villanova, PA, USA
brian.copley@bms.com
Josef Coresh, MD, PhD
Johns Hopkins University
Baltimore, USA
Atherosclerosis Risk in Communities
(ARIC)
coresh@jhu.edu
Paul de Jong, MD, PhD
University Hospital Groningen
Groningen, The Netherlands
Prevention of REnal and Vascular End stage
Disease (PREVEND)
p.e.de.jong@int.azg.nl
Page 2 of 8
Dick de Zeeuw, MD, PhD
University Medical Center Groningen
Groningen, The Netherlands
Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan
(RENAAL)
d.de.zeeuw@med.umcg.nl
Garabed Eknoyan, MD
Baylor College of Medicine
Houston, USA
geknoyan@bcm.edu
Bjørn Odvar Eriksen, MD, PhD
University Hospital of North Norway
Tromsø, Norway
The Tromsø Study
bjorn.odvar.eriksen@unn.no
Marie Evans, MD
Karolinska University Hospital
Huddinge, Sweden
ORFAN Follow-up study (OFUS)
Marie.Evans@ki.se
Armand Famiglietti
Invited Observer
Mitsubishi Tanabe Pharma Corporation
Warren, NJ USA
Armand_Famiglietti@mt-pharma-us.com
Richard Glassock, MD, MACP
Invited Speaker
UCLA David Geffen School of Medicine
Los Angeles, USA
glassock@cox.net
Stein Hallan, MD, PhD
St. Olav University Hospital
Trondheim, Norway
Health Study of Nord Trøndelag (HUNT)
stein.hallan@ntnu.no
Ali Hariri, MD
Invited Observer
Takeda Pharmaceuticals
Deerfield, IL, USA
ali.hariri@tpna.com
Brenda Hemmelgarn, MD, PhD, FRCPC
Invited Speaker
Foothills Medical Center
Calgary, Canada
Alberta Kidney Disease Network (AKDN)
brenda.hemmelgarn@albertahealthservices.ca
Alan Hull, MD
Renal Management, Inc.
Dallas, USA
alanhull@sbcglobal.net
Caroline Fox, MD, MPH
National Heart, Lung and Blood Institute
Framingham, USA
Framingham Heart Study
foxca@nhlbi.nih.gov
Eynu Imai, MD, PhD
Osaka University Graduate School of
Medicine.
Osaka, Japan
CKD-Japanese Cohort (CKD-JAC)
ADS12069@nifty.com
Marc Froissart, MD, PhD
Paris Descartes University, Georges
Pompidou European Hospital
Paris, France
NephroTest
marc.froissart@egp.aphp.fr
Ólafur Skúli Indriðason, MD, MHS
Landspitali University Hospital
Reykjavik, Iceland
Age, Gene, Environment, Susceptibility
(AGES)-Reykjavik Study
olasi@landspitali.is
Page 3 of 8
Kunitoshi Iseki, MD
University Hospital of the Ryukyus
Nishihara, Japan
Okinawa General Health Maintenance
Association (OGHMA) and Okinawa
Dialysis Study (OKIDS) registry
chihokun@med.u-ryukyu.ac.jp
Andrzej Krolewski, MD, PhD
Joslin Diabetes Center
Boston, USA
Predictors of End Stage Renal Disease in
Patients with Type 1 Diabetes and
Proteinuria
andrzej.krolewski@joslin.harvard.edu
Areef Ishani, MD, MS
University of Minnesota, Minneapolis VA
Medical Center
Minneapolis, USA
Multiple Risk Factor Intervention Trial
(MRFIT)
areef.ishani@va.gov
Florian Kronenberg, MD
University of Innsbruck Medical School
Innsbruck, Austria
Mild to Moderate Kidney Disease (MMKD)
Study
Florian.Kronenberg@i-med.ac.at
Tazeen Jafar, MD, MPH
Aga Khan University
Karachi, Pakistan
Control of Blood Pressure and Risk
Attenuation
Tazeen.jafar@aku.edu
Simerjot Jassal, MD
University of California-San Diego
San Diego, USA
Rancho Bernardo Study
sjassal@ucsd.edu
Sun Ha Jee, PhD, MPH
Yonsei University
Seoul, Korea
Severance Cohort Study
jsunha@yuhs.ac
Hanneke Joosten, MD
University Medical Centre Groningen
Zwolle, The Netherlands
ZODIAC: Zwolle Outpatient Diabetes
project Involving Available Care
j.m.h.joosten@isala.nl
Norbert Lameire, MD
Ghent University Hospital
Ghent, Belgium
norbert.lameire@ugent.be
Martin Landray, PhD, MRCP
University of Oxford
Oxford, UK
Chronic Renal Impairment in Birmingham
(CRIB) Study
martin.landray@ctsu.ox.ac.uk
Brian Lee, MD
Kaiser Permanente Clinic
Honolulu, USA
Kaiser Permanente - Hawaiian Cohort
Brian.J.Lee@kp.org
Adeera Levin, MD
St. Paul's Hospital
Vancouver, Canada
British Columbia CKD Provincial Database
and Canadian Care Prior to Dialysis (CANCARE)
KDIGO Executive Committee
alevin@providencehealth.bc.ca
Page 4 of 8
Nathan Levin, MD
Renal Research Institute
New York, USA
KDIGO Executive Committee
nlevin@rriny.com
Alison MacLeod, MB ChB, MD, FRCP
University of Aberdeen
Aberdeen, UK
KDIGO Executive Committee
mmd175@abdn.ac.uk
Johannes Mann, MD
Munich General Hospitals
Heidelberg, Germany
ONgoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint
Trial (ONTARGET) /Telmisartan
Randomised AssessmeNt Study in ACE
iNtolerant subjects with cardiovascular
Disease (TRANSCEND) Study
prof.j.mann@googlemail.com
William McClellan, MD, MPH
Invited Speaker
Emory University School of Medicine
Atlanta, USA
Renal - REasons for Geographic And Racial
Differences in Stroke (REGARDS) Study
wmcclel@sph.emory.edu
Hirohito Metoki, MD
Tohoku University Graduate School of
Medicine
Tohoku, Japan
Ohasama Study
hmetoki@mail.tains.tohoku.ac.jp
Greg Miller, PhD
Invited Speaker
Virginia Commonwealth University
Richmond, USA
gmiller@mcvh-vcu.edu
Paul Muntner, PhD
University of Alabama at Birmingham
Birmingham, USA
Renal - REasons for Geographic And Racial
Differences in Stroke (REGARDS) Study
pmuntner@uab.edu
Robert Nelson, MD, PhD
National Institute of Diabetes & Digestive &
Kidney Disease
Phoenix, USA
Pima Indian Longitudinal Study of Diabetes
and Its Complications
rgnelson@mail.nih.gov
Dorothea Nitsch, MD, MSc
London School of Hygiene and Tropical
Medicine
London, UK
Chronic kidney disease and mortality risk in
older people: a community-based population
study in the United Kingdom.
Dorothea.Nitsch@lshtm.ac.uk
Donal O'Donoghue, MB ChB, FRCP
Salford Royal NHS Foundation Trust, Hope
Hospital
Salford, UK
donal.odonoghue@srft.nhs.uk
Ann O'Hare, MD
VA Puget Sound Health Care System
Seattle, USA
Prevalence and Progression of Chronic
Kidney Disease in Veterans
ann.ohare@va.gov
Runolfur Palsson, MD, FACP, FACN
Landspitali University Hospital
Reykjavik, Iceland
Age, Gene, Environment, Susceptibility
(AGES)-Reykjavik Study
runolfur@landspitali.is
Page 5 of 8
Annalisa Perna, Stat.Sci.D
Mario Negri Institute for Pharmacological
Research
Bergamo, Italy
Ramipril Efficacy In Nephropathy (REIN
and REIN2)
Annalisa.Perna@marionegri.it
Kevan Polkinghorne, MBChB, MClinEpi,
FRACP, PhD
Monash Medical Centre & Monash
University
Melbourne, Australia
Australian Diabetes, Obesity and Lifestyle
(AusDiab I & II) Study
kevan.polkinghorne@med.monash.edu.au
Mahboob Rahman, MD
Cleveland Clinic
Cleveland, USA
Chronic Renal Insufficiency Cohort (CRIC)
Study
Mahboob.Rahman@UHhospitals.org
Miguel Riella, MD, PhD
Catholic University of Parana
Curitiba, Brazil
KDIGO Executive Committee
mcriella@pro-renal.org.br
Michael Rocco, MD, MSCE
Wake Forest University
Winston Salem, USA
mrocco@wfubmc.edu
Paul Roderick, MD
University of Southampton
Southampton, UK
Chronic kidney disease and mortality risk in
older people: a community-based population
study in the United Kingdom
pjr@soton.ac.uk
Peter Rossing, MD, DMSc
Steno Diabetes Center
Gentofte, Denmark
STENO Diabetes Center Study
pro@steno.dk
Dietrich Rothenbacher, MD, MPH
Universitats Klinikum Heidelberg
Heidelberg, Germany
ESTHER-study (Germany)
d.rothenbacher@dkfz-heidelberg.de
Mark Sarnak, MD, MS
Tufts Medical Center
Boston, USA
Modification of Diet in Renal Disease
(MDRD) Study
msarnak@tuftsmedicalcenter.org
Robert Schrier, MD
University of Colorado Health Services
Center
Denver, USA
KDIGO Executive Committee
robert.schrier@uchsc.edu
Anoop Shankar, MD, PhD
Center for Interdisciplinary Research in
Cardiovascular Sciences
Morgantown, USA
Beaver Dam Chronic Kidney Disease Study
ashankar@hsc.wvu.edu
Michael Shlipak, MD, MPH
Invited Speaker
Veteran's Affairs Medical Center
San Francisco, USA
Multi-Ethnic Study of Atherosclerosis
(MESA) & Cardiovascular health Study
michael.shlipak@ucsf.edu
Page 6 of 8
David Smith, RPh, MHA, PhD
Kaiser Permanente Center for Health
Research
Portland, USA
Kaiser Pacific Northwest: Developing a
Risk Equation to Predict Mortality and
Progression to End Stage Renal Disease
david.h.smith@kpchr.org
Benedicte Stengel, MD, PhD
INSERM
Villejuif, France
NephroTest
benedicte.stengel@inserm.fr
Lesley Stevens, MD, MS
Invited Speaker
Tufts Medical Center
Boston, USA
lstevens1@tuftsmedicalcenter.org
Paul Stevens, MBBS, BSc, FRCP
Kent and Canterbury Hospital
Canterbury, UK
Paul.Stevens@ekht.nhs.uk
Nihad A.M. Tamimi, MD
Invited Observer
Pfizer Global Research & Development
Canterbury, United Kingdom
Nihad.tamimi@pfizer.com
Marcello Tonelli, MD
University of Alberta
Edmonton, Canada
Cholesterol and Recurrent Events Study
(CARE)
mtonelli@ualberta.ca
Yusuke Tsukamoto, MD
Shuwa General Hospital
Tokyo, Japan
KDIGO Executive Committee
tsukamoto@jinzou.net
Katrin Uhlig, MD, MS
Tufts Medical Center
Boston, USA
kuhlig@tuftsmedicalcenter.org
Anil Upadhyay, MD
Invited Observer
Mitsubishi Pharma Europe Ltd
London, UK
AUpadhyay@m-pharma.co.uk
Raymond Vanholder, MD, PhD
University Hospital Ghent
Ghent, Belgium
KDIGO Executive Committee
Raymond.Vanholder@ugent.be
Joseph Vassalotti, MD
National Kidney Foundation
New York, USA
JoeV@kidney.org
Fang Wang, MD
Peking University
Beijing, China
Beijing Cohort: 5 years follow- up for the
population survey of citizens older than 40
wangfang@bjmu.edu.cn
HaiYan Wang, MD
Peking University
Beijing, China
Beijing Cohort: 5 years follow- up for the
population survey of citizens older than 40
why@bjmu.edu.cn
David Warnock, MD
University of Alabama at Birmingham
Birmingham, USA
Renal - REasons for Geographic And Racial
Differences in Stroke (REGARDS) Study
dwarnock@uab.edu
Page 7 of 8
Chi-Pang Wen, MD, MPH, DrPH
University of Wisconsin
Madison, USA
Taiwan Cohort
cwengood@nhri.org.tw
Sung-Feng Wen, MD
University of Wisconsin
Madison, USA
Taiwan Cohort
sfw@medicine.wisc.edu
Jessica Robin Weinstein, MD
Oregon Health and Sciences University
Portland, USA
Kaiser Pacific Northwest: Developing a
Risk Equation to Predict Mortality and
Progression to End Stage Renal Disease
Jessica.R.Weinstein@kpchr.org
Jack Wetzels, MD, PhD
Radboud University Nijmegen Medical
Center
Nijmegen, The Netherlands
MASTERPLAN
j.wetzels@nier.umcn.nl
David Wheeler, MD, FRCP
Royal Free and University College Medical
School
London, UK
Chronic Renal Impairment in Birmingham
(CRIB) Study
KDIGO Executive Committee
d.wheeler@medsch.ucl.ac.uk
Desmond Williams, MD, PhD
Centers for Disease Control and Prevention
Atlanta, USA
DEWilliams@cdc.gov
Dan Wilson, MD
Invited Observer
Pfizer Medical Director
New York, USA
DanielJ.Wilson@pfizer.com
Christopher Winearls, MB, FRCP, DPhil
Oxford Kidney Unit, Oxford University
Oxford, UK
chris.winearls@orh.nhs.uk
Mark Woodward, MD
Mt. Sinai School of Medicine
New York, USA
The Action in Diabetes and Vascular
disease: preterAx and diamicroN-MR
Controlled Evaluation (ADVANCE) study
Mark.Woodward@mountsinai.org
Jackson Wright, MD , PhD, FACP
Case Western Reserve University
Cleveland, USA
African American Study of Kidney Disease
and Hypertension (AASK) Cohort Study
jxw20@case.edu
Page 8 of 8